DexCom is a major player in the continuous glucose monitoring space, with steadily growing revenues and a breakout year in 2020. DXCM's market cap valuation has reached $40 billion, leading to high ...

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...

Mar. 19, 2025 4:00 AM ETDexCom, Inc. (DXCM) “With policymakers increasingly focused on digital transformation in healthcare, now is the time to push for greater investment in CGM technology as a core ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A copy of the same can be downloaded here. Select Growth primarily targets U.S ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Dexcom has launched a proprietary Generative AI platform. The company said that the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...

As the year comes to a close, it's time to look back at the numerous innovations across the diabetes technology industry in ...

Dexcom, a global leader in real time continuous glucose monitoring for people with diabetes, is releasing the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1 ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...